Deptor Enhances Triple-Negative Breast Cancer Metastasis and Chemoresistance through Coupling to Survivin Expression

Neoplasia (United States)

Volumn 17, Issue 3, 2015, Pages 317-328

  Parvani, Jenny G ^a   Davuluri, Gangarao ^b   Wendt, Michael K ^c   Espinosa, Christine ^a   Tian, Maozhen ^a   Danielpour, David ^a   Sossey Alaoui, Khalid ^b   Schiemann, William P ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA3 INTEGRIN; CK19 PROTEIN; DOXORUBICIN; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; FULVESTRANT; HYDROGEN PEROXIDE; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PROTEIN; S6 KINASE; SMAD3 PROTEIN; SURVIVIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; BIRC5 PROTEIN, HUMAN; CASPASE; DEPTOR PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; SIGNAL PEPTIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CELL SURVIVAL; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84964693864     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.02.003     Document Type: Article

References (62)

1. [1] Moses, H, Barcellos-Hoff, MH, TGF-β biology in mammary development and breast cancer. Cold Spring Harb Perspect Biol, 3, 2011, a003277.
2. [2] Band, AM, Laiho, M, Crosstalk of TGF-β and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 16 (2011), 109–115.
3. [3] Tian, M, Schiemann, WP, The TGF-β paradox in human cancer: An update. Future Oncol 5 (2009), 259–271.
4. [4] Morrison, CD, Parvani, JG, Schiemann, WP, The relevance of the TGF-β paradox to EMT-MET programs. Cancer Lett 341 (2013), 30–40.
5. [5] Taylor, MA, Parvani, JG, Schiemann, WP, The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-β in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 15 (2010), 169–190.
6. [6] Parvani, JG, Taylor, MA, Schiemann, WP, Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 16 (2011), 127–146.
7. [7] Saitoh, M, Miyazawa, K, Transcriptional and post-transcriptional regulation in TGF-β-mediated epithelial-mesenchymal transition. J Biochem 151 (2012), 563–571.
8. [8] Massague, J, TGFβ signalling in context. Nat Rev Mol Cell Biol 13 (2012), 616–630.
9. [9] Katsuno, Y, Lamouille, S, Derynck, R, TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25 (2013), 76–84.
10. [10] Heldin, CH, Vanlandewijck, M, Moustakas, A, Regulation of EMT by TGFβ in cancer. FEBS Lett 586 (2012), 1959–1970.
11. [11] Mani, SA, Guo, W, Liao, MJ, Eaton, EN, Ayyanan, A, Zhou, AY, Brooks, M, Reinhard, F, Zhang, CC, Shipitsin, M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
12. [12] Shipitsin, M, Campbell, LL, Argani, P, Weremowicz, S, Bloushtain-Qimron, N, Yao, J, Nikolskaya, T, Serebryiskaya, T, Beroukhim, R, Hu, M, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11 (2007), 259–273.
13. [13] Ben-Porath, I, Thomson, MW, Carey, VJ, Ge, R, Bell, GW, Regev, A, Weinberg, RA, An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40 (2008), 499–507.
14. [14] Creighton, CJ, Chang, JC, Rosen, JM, Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 15 (2010), 253–260.
15. [15] Creighton, CJ, Li, X, Landis, M, Dixon, JM, Neumeister, VM, Sjolund, A, Rimm, DL, Wong, H, Rodriguez, A, Herschkowitz, JI, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106 (2009), 13820–13825.
16. [16] Wang, Z, Zhong, J, Inuzuka, H, Gao, D, Shaik, S, Sarkar, FH, Wei, W, An evolving role for DEPTOR in tumor development and progression. Neoplasia 14 (2012), 368–375.
17. [17] Peterson, TR, Laplante, M, Thoreen, CC, Sancak, Y, Kang, SA, Kuehl, WM, Gray, NS, Sabatini, DM, DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137 (2009), 873–886.
18. [18] Zhao, Y, Xiong, X, Sun, Y, DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell 44 (2011), 304–316.
19. [19] Luo, Z, Yu, G, Lee, HW, Li, L, Wang, L, Yang, D, Pan, Y, Ding, C, Qian, J, Wu, L, et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res 72 (2012), 3360–3371.
20. [20] Pei, L, Xie, P, Zhou, E, Yang, Q, Luo, Y, Tang, Z, Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma. Mol Med Rep 4 (2011), 817–823.
21. [21] Carrasco, DR, Tonon, G, Huang, Y, Zhang, Y, Sinha, R, Feng, B, Stewart, JP, Zhan, F, Khatry, D, Protopopova, M, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9 (2006), 313–325.
22. [22] Chen, R, Yang, Q, Lee, JD, BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt/GSK3β signaling pathway. Cancer Res 72 (2012), 1579–1587.
23. [23] Wendt, MK, Smith, JA, Schiemann, WP, Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29 (2010), 6485–6498.
24. 3 integrin and Src facilitate transforming growth factor-β mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res, 8, 2006, R42.
25. [25] Wendt, MK, Taylor, MA, Schiemann, BJ, Schiemann, WP, Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell 22 (2011), 2423–2435.
26. [26] Wendt, MK, Schiemann, WP, Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis. Breast Cancer Res, 11, 2009, R68.
27. [27] Wendt, MK, Smith, JA, Schiemann, WP, p130Cas is required for mammary tumor growth and transforming growth factor-β-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem 284 (2009), 34145–34156.
28. [28] Balanis, N, Wendt, MK, Schiemann, BJ, Wang, Z, Schiemann, WP, Carlin, CR, Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem 288 (2013), 17954–17967.
29. [29] Taylor, MA, Amin, JD, Kirschmann, DA, Schiemann, WP, Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells. Neoplasia 13 (2011), 406–418.
30. [30] Paszek, MJ, Zahir, N, Johnson, KR, Lakins, JN, Rozenberg, GI, Gefen, A, Reinhart-King, CA, Margulies, SS, Dembo, M, Boettiger, D, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8 (2005), 241–254.
31. [31] Balanis, N, Yoshigi, M, Wendt, MK, Schiemann, WP, Carlin, CR, β3 integrin–EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol Biol Cell 22 (2011), 4288–4301.
32. [32] Taylor, MA, Sossey-Alaoui, K, Thompson, CL, Danielpour, D, Schiemann, WP, TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 123 (2013), 150–163.
33. [33] Wendt, MK, Schiemann, BJ, Parvani, JG, Lee, YH, Kang, Y, Schiemann, WP, TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene 32 (2013), 2005–2015.
34. [34] Wander, SA, Hennessy, BT, Slingerland, JM, Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 121 (2011), 1231–1241.
35. [35] Cidado, J, Park, BH, Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 17 (2012), 205–216.
36. [36] Petrel, TA, Brueggemeier, RW, Increased proteasome-dependent degradation of estrogen receptor-α by TGF-β1 in breast cancer cell lines. J Cell Biochem 88 (2003), 181–190.
37. [37] Jinnin, M, Ihn, H, Tamaki, K, Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-β1-induced extracellular matrix expression. Mol Pharmacol 69 (2006), 597–607.
38. [38] Yang, SH, Galanis, A, Sharrocks, AD, Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol Cell Biol 19 (1999), 4028–4038.
39. [39] Gellibert, F, Woolven, J, Fouchet, MH, Mathews, N, Goodland, H, Lovegrove, V, Laroze, A, Nguyen, VL, Sautet, S, Wang, R, et al. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-β type I receptor inhibitors. J Med Chem 47 (2004), 4494–4506.
40. [40] Inman, GJ, Nicolas, FJ, Callahan, JF, Harling, JD, Gaster, LM, Reith, AD, Laping, NJ, Hill, CS, SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62 (2002), 65–74.
41. [41] Fu, J, Zhang, L, He, T, Xiao, X, Liu, X, Wang, L, Yang, L, Yang, M, Zhang, T, Chen, R, et al. TWIST represses estrogen receptor-α expression by recruiting the NuRD protein complex in breast cancer cells. Int J Biol Sci 8 (2012), 522–532.
42. [42] Wik, E, Raeder, MB, Krakstad, C, Trovik, J, Birkeland, E, Hoivik, EA, Mjos, S, Werner, HM, Mannelqvist, M, Stefansson, IM, et al. Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res 19 (2013), 1094–1105.
43. [43] Taube, JH, Herschkowitz, JI, Komurov, K, Zhou, AY, Gupta, S, Yang, J, Hartwell, K, Onder, TT, Gupta, PB, Evans, KW, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 107 (2010), 15449–15454.
44. [44] Taddei, ML, Giannoni, E, Comito, G, Chiarugi, P, Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett 341 (2013), 80–96.
45. [45] Turner, N, Moretti, E, Siclari, O, Migliaccio, I, Santarpia, L, D'Incalci, M, Piccolo, S, Veronesi, A, Zambelli, A, Del Sal, G, et al. Targeting triple negative breast cancer: is p53 the answer?. Cancer Treat Rev 39 (2013), 541–550.
46. [46] Frederick, JP, Liberati, NT, Waddell, DS, Shi, Y, Wang, XF, Transforming growth factor β-mediated transcriptional repression of c-Myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol 24 (2004), 2546–2559.
47. [47] Matsuda, T, Yamamoto, T, Muraguchi, A, Saatcioglu, F, Cross-talk between transforming growth factor-β and estrogen receptor signaling through Smad3. J Biol Chem 276 (2001), 42908–42914.
48. [48] Lehmann, BD, Bauer, JA, Chen, X, Sanders, ME, Chakravarthy, AB, Shyr, Y, Pietenpol, JA, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121 (2011), 2750–2767.
49. [49] Burstein, MD, Tsimelzon, A, Poage, GM, Covington, KR, Contreras, A, Fuqua, S, Savage, M, Osborne, CK, Hilsenbeck, SG, Chang, JC, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0432.
50. [50] Chang, BH, Gujral, TS, Karp, ES, BuKhalid, R, Grantcharova, VP, MacBeath, G, A systematic family-wide investigation reveals that ~ 30% of mammalian PDZ domains engage in PDZ-PDZ interactions. Chem Biol 18 (2011), 1143–1152.
51. [51] Ivarsson, Y, Plasticity of PDZ domains in ligand recognition and signaling. FEBS Lett 586 (2012), 2638–2647.
52. [52] Wawrzyniak, AM, Kashyap, R, Zimmermann, P, Phosphoinositides and PDZ domain scaffolds. Adv Exp Med Biol 991 (2013), 41–57.
53. [53] Baenke, F, Peck, B, Miess, H, Schulze, A, Hooked on fat: The role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech 6 (2013), 1353–1363.
54. [54] Halaoui, R, McCaffrey, L, Rewiring cell polarity signaling in cancer. Oncogene 34 (2014), 939–950.
55. [55] Evdokimova, V, Tognon, C, Ng, T, Sorensen, PH, Reduced proliferation and enhanced migration: Two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 8 (2009), 2901–2906.
56. [56] Vega, S, Morales, AV, Ocana, OH, Valdes, F, Fabregat, I, Nieto, MA, Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 18 (2004), 1131–1143.
57. [57] Corominas-Faja, B, Cufi, S, Oliveras-Ferraros, C, Cuyas, E, Lopez-Bonet, E, Lupu, R, Alarcon, T, Vellon, L, Iglesias, JM, Leis, O, et al. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle 12 (2013), 3109–3124.
58. [58] Kadota, M, Yang, HH, Gomez, B, Sato, M, Clifford, RJ, Meerzaman, D, Dunn, BK, Wakefield, LM, Lee, MP, Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One, 5, 2010, e9201.
59. [59] Yang, J, Song, K, Krebs, TL, Jackson, MW, Danielpour, D, Rb/E2F4 and Smad2/3 link survivin to TGF-β-induced apoptosis and tumor progression. Oncogene 27 (2008), 5326–5338.
60. [60] Coumar, MS, Tsai, FY, Kanwar, JR, Sarvagalla, S, Cheung, CH, Treat cancers by targeting survivin: just a dream or future reality?. Cancer Treat Rev 39 (2013), 802–811.
61. [61] Cheung, CH, Huang, CC, Tsai, FY, Lee, JY, Cheng, SM, Chang, YC, Huang, YC, Chen, SH, Chang, JY, Survivin—biology and potential as a therapeutic target in oncology. Onco Targets Ther 6 (2013), 1453–1462.
62. [62] Carmena, M, Pinson, X, Platani, M, Salloum, Z, Xu, Z, Clark, A, Macisaac, F, Ogawa, H, Eggert, U, Glover, DM, et al. The chromosomal passenger complex activates Polo kinase at centromeres. PLoS Biol, 10, 2012, e1001250.